Peptide targeting of adenoviral vectors to augment tumor gene transfer

Cancer Gene Therapy

Volumn 19, Issue 7, 2012, Pages 476-488

  Ballard, E N ^a   Trinh, V T ^a   Hogg, R T ^a   Gerard, R D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

adenovirus; aminopeptidase N; integrin; peptide; targeting; tumor

Indexed keywords

ADENOVIRUS VECTOR; ALANINE; ALANINE SERINE LEUCINE; ARGININE; ARGINYLGLYCYLASPARTIC ACID; ASPARAGINE GLYCINE ARGININE; CAPSID PROTEIN; CELL SURFACE RECEPTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CELL LINE; CELL TYPE; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; GENE TRANSFER; HEPATITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; TUMOR GENE; VIRUS INFECTIVITY;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CELL LINE, TUMOR; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; FEASIBILITY STUDIES; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; PEPTIDES; RECEPTORS, VIRUS;

ADENOVIRIDAE; MIRIDAE;

EID: 84863724593     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.23     Document Type: Article

References (62)

1. Huard J, Lochmü ller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107-115.
2. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-409. (Pubitemid 24308308)
3. van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FH, van Krieken JH, van der Eb AJ et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 1998; 5: 451-458. (Pubitemid 28200636)
4. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816. (Pubitemid 23113507)
5. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356. (Pubitemid 27157315)
6. Nemerow GR, Pache L, Reddy V, Stewart PL. Insights into adenovirus host cell interactions from structural studies. Virology 2009; 384: 380-388.
7. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E. Simultaneous CAR-and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003; 8: 485-494. (Pubitemid 37161470)
8. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75: 11284-11291. (Pubitemid 33063218)
9. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR-and alphav integrin-binding ablation. J Virol 2003; 77: 13062-13072. (Pubitemid 37494302)
10. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 2006; 87(Pt 9): 2487-2495.
11. Nicklin SA, Wu E, Nemerow GR, Baker AH. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384-393. (Pubitemid 41150124)
12. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409. (Pubitemid 351200513)
13. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008; 105: 5483-5488. (Pubitemid 351753889)
14. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 2008; 16: 1474-1480.
15. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780. (Pubitemid 32768981)
16. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382-390. (Pubitemid 30159987)
17. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595-1604. (Pubitemid 37452870)
18. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003; 14: 777-787. (Pubitemid 36623514)
19. Hogg RT, Thorpe P, Gerard RD. Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther 2011; 18: 275-287.
20. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000; 10: 435-442. (Pubitemid 32181913)
21. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 1995; 13: 265-270.
22. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997; 15: 542-546. (Pubitemid 27251571)
23. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62: 867-874. (Pubitemid 34126966)
24. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-727. (Pubitemid 30094573)
25. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380. (Pubitemid 28063372)
26. Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007; 18: 1189-1200. (Pubitemid 47480744)
27. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003; 63: 7400-7409. (Pubitemid 37413482)
28. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006; 66: 10073-10082. (Pubitemid 44672061)
29. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8: 730-735. (Pubitemid 32496435)
30. Majhen D, Gabrilovac J, Eloit M, Richardson J, Ambriović-Ristov A. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N. Biochem Biophys Res Commun 2006; 348: 278-287. (Pubitemid 44164675)
31. Jullienne B, Vigant F, Muth E, Chaligné R, Bouquet C, Giraudier S et al. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther 2009; 16: 1405-1415.
32. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 2009; 20: 1214-1221.
33. Rein DT, Breidenbach M, Wu H, Han T, Haviv YS, Wang M et al. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer 2004; 111: 698-704. (Pubitemid 39062891)
34. Li P, Liu Y, Maynard J, Tang Y, Deisseroth A. Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma. Mol Ther 2010; 18: 921-928.
35. Singh R, Kostarelos K. Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol 2009; 27: 220-229.
36. Kritz AB, Nicol CG, Dishart KL, Nelson R, Holbeck S, Von Seggern DJ et al. Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther 2007; 15: 741-749. (Pubitemid 46431994)
37. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
38. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, M Mehtali Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810. (Pubitemid 26187479)
39. Gerard RD, Meidell RS. Adenovirus vectors. In: Hames BD, Glover D, (eds). DNA Cloning: A Practical Approach. Oxford University Press: Oxford, 1995 pp 285-307.
40. Von Seggern DJ, Huang S, Fleck SK, Stevenson SC, Nemerow GR. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol 2000; 74: 354-362. (Pubitemid 30002916)
41. Hogg RT, Garcia JA, Gerard RD. Adenoviral targeting of gene expression to tumors. Cancer Gene Ther 2010; 17: 375-386.
42. Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol 1994; 68: 5239-5246. (Pubitemid 24226593)
43. Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res 2009; 143: 184-194.
44. Xia D, Henry LJ, Gerard RD, Deisenhofer J. Crystal structure of the receptorbinding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994; 2: 1259-1270. (Pubitemid 124001323)
45. Pandha HS, Stockwin LH, Eaton J, Clarke IA, Dalgleish AG, Todryk SM et al. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003; 6: 6-11. (Pubitemid 36432614)
46. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT et al. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007; 48: 1536-1544. (Pubitemid 47397404)
47. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirusadenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647-1653. (Pubitemid 35034684)
48. Bilbao R, Reay DP, Hughes T, Biermann V, Volpers C, Goldberg L et al. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors. Gene Ther 2003; 10: 1821-1829. (Pubitemid 37185140)
49. Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y, Hayakawa T. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 2003; 5: 267-276. (Pubitemid 40310379)
50. Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW et al. CARdependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103: 579-587. (Pubitemid 29094059)
51. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6: 1336-1339. (Pubitemid 29359030)
52. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001; 40: 2373-2378. (Pubitemid 32171709)
53. Kirby I, Lord R, Davison E, Wickham TJ, Roelvink PW, Kovesdi I et al. Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes. J Virol 2001; 75: 7210-7214. (Pubitemid 32641612)
54. Niu G, Xiong Z, Cheng Z, Cai W, Gambhir SS, Xing L et al. In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol Imaging Biol 2007; 9: 126-134. (Pubitemid 46705706)
55. Xiong Z, Cheng Z, Zhang X, Patel M, Wu JC, Gambhir SS et al. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 2006; 47: 130-139. (Pubitemid 46768522)
56. Minea RO, Helchowski CM, Zidovetzki SJ, Costa FK, Swenson SD, Markland FS##Jr. Vicrostatin-an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One 2010; 5: e10929.
57. Demaegdt H, Lenaerts PJ, Swales J, De Backer JP, Laeremans H, Le MT et al. Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme. Eur J Pharmacol 2006; 546: 19-27. (Pubitemid 44331842)
58. Garrigues HJ, Rubinchikova YE, Dipersio CM, Rose TM. Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. J Virol 2008; 82: 1570-1580.
59. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 2003; 10: 695-704. (Pubitemid 37089844)
60. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S et al. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer 2007; 7: 140.
61. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003; 55: 71-80. (Pubitemid 36397747)
62. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 2000; 60: 3429-3434.